ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Sanaria Readies New Malaria Vaccine

November 5, 2007 | APPEARED IN VOLUME 85, ISSUE 45

Sanaria and the PATH Malaria Vaccine Initiative (MVI) have opened a plant in Rockville, Md., to manufacture the first vaccine using a weakened malaria parasite. Overcoming obstacles to large-scale production, Sanaria's approach involves safely raising aseptically produced mosquitoes carrying Plasmodium falciparum, irradiating them to weaken the parasite, and then harvesting the parasite from the insects' salivary glands. Sanaria plans to begin clinical testing next year. Along with MVI, Sanaria has support from NIH and the Department of Defense.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment